Evaluating the Use of Oral Indapamide to Reduce Disabiltiy Progression in Progressive Multiple Sclerosis (MS)

NCT07765212 | Not Yet Recruiting Phase 2 FDA Drug

• 1 other identifier: 2026-525260-18-00
• Study Type: interventional
• Target: 75
• Locations: 0 countries
• Sites: N/A

Brief Summary

The goal of this clinical trial is to determine whether treatment with indapamide can slow the rate of progression in patients with progressive forms of multiple sclerosis (MS). The main question it aims to answer is whether this treatment can reduce the speed at which the walking speed of patients with progressive MS (PMS) worsens. Participants will take an indapamide tablet once daily for 12 months. During this time, among others, their walking speed will be assessed several times.

Conditions

Multiple Sclerosis

Keywords

Indapamide; Futility trial; Progressive Multiple Sclerosis; PMS; PPMS; SPMS; Primary Progressive Multiple Sclerosis; Secondary Progressive Multiple Sclerosis; Timed 25 foot walk; T25FW

Outcome Measures

Primary Outcomes (1)

• Number of participants with 20% or more worsening in timed 25 foot walk between the Baseline and the 12 Months follow-up study visit.

  The T25FW is the time it takes for the participant to walk 25 feet, averaged over two trials. Significant worsening is defined as a more than or equal to 20 percent increase in the T25FW.

  12 months

Study Arms (1)

Indapamide

EXPERIMENTAL

Once daily oral 2.5mg indapamide

Drug: Indapamide

Interventions

Indapamide DRUG

No study has previously investigated the effect of indapamide in persons with MS.

Indapamide

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Written informed consent obtained
• Aged between 18 and 65 years
• Diagnosed with PPMS or SPMS, according to current diagnostic criteria
• Screening Expanded Disability Status Scale score between 4.0 and 6.5 inclusive.
• Screening T25FW (average of two trials) of 5 seconds or more for people with PPMS, or of 9 seconds or more for people with SPMS
• Use of effective methods of contraception for women of childbearing potential.

You may not qualify if:

• Individuals with renal insufficiency and an eGFR below 30ml/min per 1.73 m2
• Individuals with a blood pressure below 110 mmHg systolic or 70 mmHg diastolic
• Individuals with significant hepatic impairment (pre-existing or developing during the trial)
• Individuals with clinically significant abnormal screening labs
• Individuals with cardiac arrhythmia
• Individuals with a prolonged QT interval: individuals with frequency corrected QT (QTc) intervals of more than 450ms (men) or 470ms (women) at the screening examination will not be included in the study, and participants with QTc intervals of greater than 500ms on any of the other ECG examinations throughout the study will be excluded from the study.
• Individuals who are pregnant or currently breast-feeding
• Individuals with an allergy or other intolerability to IND
• Individuals who use Fampridine or 4-aminopyridine
• Individuals who start Fampridine or 4-aminopyridine during the trial
• Individuals who start Baclofen or Tizanidine during the trial
• Individuals who increase the dose of Baclofen or Tizanidine during the trial
• Individuals who receive treatment with Botulinum toxin in the leg muscles during the trial
• Individuals who use siponimod, ocrelizumab, natalizumab or other disease-modifying treatment for RRMS
• Concomitant use of corticosteroids

Sponsors & Collaborators

• Eva M.M. Strijbis: lead

MeSH Terms

Conditions

Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive

Interventions

Indapamide

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Sulfonamides; Amides; Organic Chemicals; Sulfones; Sulfur Compounds; Indoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Central Study Contacts

Wouter C Meijer, MD

CONTACT

+31 0625716262; w.c.meijer@amsterdamumc.nl

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Dr. E.M.M. Strijbis, Neurologist

Study Record Dates

• First Submitted: August 10, 2026
• First Posted: August 14, 2026
• Study Start (Estimated): September 1, 2026
• Primary Completion (Estimated): September 1, 2028
• Study Completion (Estimated): September 1, 2028
• Last Updated: August 14, 2026

Record last verified: 2026-08

Data Sharing

• IPD Sharing: Will not share